Industry Newsglp 1obesity drugslillyearnings
Eli Lilly Raises 2026 Guidance, Orforglipron Launch
7.2
On Feb. 5 Eli Lilly reported a stronger-than-expected Q4 with EPS $7.54 and revenue $19.3 billion, and issued 2026 guidance projecting roughly 25% revenue growth. Goldman Sachs raised its price target to $1,260 and reiterated a Buy rating after the results. Management said Lilly plans a U.S. launch of oral obesity drug orforglipron in Q2 2026, signaling confidence in GLP-1 market expansion.
Key Points
- 1Reports: Lilly posts Q4 earnings beat; Q4 EPS $7.54, revenue $19.3 billion.
- 2Highlights: Goldman raises price target to $1,260 citing ~25% 2026 revenue growth outlook.
- 3Implication: Orforglipron Q2 2026 launch could expand GLP-1 market amid pricing pressures.
Scoring Rationale
Strong official earnings, robust guidance, and an upcoming drug launch drive score, limited by its non-AI industry focus.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
